Target intelligence / Profile preview

MicroRNA 150 (miR-150)

Target
miR-150
Molecular classification
microRNA (miRNA), Non-coding RNA
01

Overview

MicroRNA 150 (miR-150) is a highly conserved, short non-coding RNA molecule that regulates gene expression at the post-transcriptional level. It is primarily expressed in mature lymphocytes (T and B cells) and plays essential roles in cell differentiation, especially during lymphocyte development, as well as in apoptosis, proliferation, migration, and angiogenesis. MiR-150 directly binds to cellular mRNAs to induce translational repression or degradation, contributing to the regulation of hematopoietic, immune, and vascular functions. In disease, miR-150 can act as either a tumor suppressor or an oncogene, particularly in cancer, and its dysregulation is associated with several malignancies, cardiovascular pathologies, and inflammatory disorders. Due to these roles, miR-150 is considered both a biomarker and a potential therapeutic target, although its dual function in various tissues complicates clinical application.

Other names
MIR150hsa-mir-150MIRN150miRNA150mir-150
02

Mechanism of action

Negative regulation of gene expression via binding to target mRNAs, resulting in translational repression or mRNA degradation. Mechanism of experimental drugs would include blockade, mimicry, or inhibition of miR-150 function.

03

Biological functions

Post-transcriptional gene regulationCell differentiationApoptosisCell proliferationImmune responseCell migrationAngiogenesis
04

Disease associations

Cancer (as both tumor suppressor and oncogene, context-dependent)Cardiovascular diseaseInflammationAutoimmune disease (e.g., rheumatoid arthritis, lupus nephritis)
05

Safety considerations

Lack of tissue specificity and dual (oncogenic and tumor suppressor) roles in different contexts present therapeutic challengesoff-target effects and toxicity concerns for RNA-targeting therapies
06

Interacting drugs

None established; however, miR-150 itself is a target for antisense oligonucleotide therapeutics and is being investigated in preclinical studies
07

Biomarkers

Expression level of miR-150 for cancer prognosis and progression (down- or up-regulation in various cancers), cardiovascular disease, and autoimmune diseases

Beyond the preview

Go deeper on MicroRNA 150 (miR-150).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 150 (miR-150).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call